Kymab Ltd

📍 Cambridge, United Kingdom🗓 Founded 2010👥 104 employees💰 Last funded Apr 2020
Biotechnology Research🌐 kymab.com
Website LinkedIn
Kymab, a Sanofi company, is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available. Kymab’s platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.
2
Total investors
0
Early stage
0
Mid stage
1
Late stage
2010
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Belgium
1
Switzerland
1
Frequently asked questions
Who invested in Kymab Ltd?
Kymab Ltd has 2 investors on record on gritt.io and 1 late-stage investors.
When did Kymab Ltd last raise funding?
The most recent investment in Kymab Ltd recorded on gritt.io was in April 2020.
When was Kymab Ltd founded?
Kymab Ltd was founded in 2010.
What industry is Kymab Ltd in?
Kymab Ltd operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Kymab Ltd based?
Kymab Ltd is headquartered in Cambridge, United Kingdom.